Published in Nature on March 25, 1993
Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol (1994) 22.96
CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med (2004) 13.55
Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci U S A (1997) 13.47
Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. Proc Natl Acad Sci U S A (1998) 5.48
Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J Virol (1994) 5.36
Administration of an anti-CD8 monoclonal antibody interferes with the clearance of chimeric simian/human immunodeficiency virus during primary infections of rhesus macaques. J Virol (1998) 5.31
CCR5 levels and expression pattern correlate with infectability by macrophage-tropic HIV-1, in vitro. J Exp Med (1997) 5.18
Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with dna and recombinant adenoviral vaccine vectors expressing Gag. J Virol (2005) 4.78
The importance of nef in the induction of human immunodeficiency virus type 1 replication from primary quiescent CD4 lymphocytes. J Exp Med (1994) 4.39
The human immunodeficiency virus type 1 vpr gene prevents cell proliferation during chronic infection. J Virol (1995) 4.19
Determination of antigen-specific memory/effector CD4+ T cell frequencies by flow cytometry: evidence for a novel, antigen-specific homeostatic mechanism in HIV-associated immunodeficiency. J Clin Invest (1997) 4.01
Alternative splicing of human immunodeficiency virus type 1 mRNA modulates viral protein expression, replication, and infectivity. J Virol (1993) 3.90
The extent of early viral replication is a critical determinant of the natural history of simian immunodeficiency virus infection. J Virol (1997) 3.77
Immunopathogenic events in acute infection of rhesus monkeys with simian immunodeficiency virus of macaques. J Virol (1994) 3.71
Human immunodeficiency virus type 1 Vpr arrests the cell cycle in G2 by inhibiting the activation of p34cdc2-cyclin B. J Virol (1995) 3.69
Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites. J Virol (1997) 3.64
Virus dynamics and drug therapy. Proc Natl Acad Sci U S A (1997) 3.63
Global genomic analysis reveals rapid control of a robust innate response in SIV-infected sooty mangabeys. J Clin Invest (2009) 3.55
Progressive CD4+ central memory T cell decline results in CD4+ effector memory insufficiency and overt disease in chronic SIV infection. J Exp Med (2007) 3.45
Development of the anti-gp120 antibody response during seroconversion to human immunodeficiency virus type 1. J Virol (1994) 3.28
Viral burden and HIV disease. Nature (1993) 3.18
ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc Natl Acad Sci U S A (1995) 3.18
Intravaginal inoculation of rhesus macaques with cell-free simian immunodeficiency virus results in persistent or transient viremia. J Virol (1994) 3.05
Human immunodeficiency virus type 1 variants with increased replicative capacity develop during the asymptomatic stage before disease progression. J Virol (1994) 3.01
HIV-1-driven regulatory T-cell accumulation in lymphoid tissues is associated with disease progression in HIV/AIDS. Blood (2006) 2.95
Simian immunodeficiency virus replicates to high levels in sooty mangabeys without inducing disease. J Virol (1998) 2.94
Efficient lysis of human immunodeficiency virus type 1-infected cells by cytotoxic T lymphocytes. J Virol (1996) 2.85
Establishment of a stable, inducible form of human immunodeficiency virus type 1 DNA in quiescent CD4 lymphocytes in vitro. J Virol (1995) 2.85
Human immunodeficiency virus infection of the human thymus and disruption of the thymic microenvironment in the SCID-hu mouse. J Exp Med (1993) 2.81
Increased mortality and AIDS-like immunopathology in wild chimpanzees infected with SIVcpz. Nature (2009) 2.78
Fusion from without directed by human immunodeficiency virus particles. J Virol (1994) 2.62
Differential regulation of the antibody responses to Gag and Env proteins of human immunodeficiency virus type 1. J Virol (1997) 2.60
Nevirapine-resistant human immunodeficiency virus: kinetics of replication and estimated prevalence in untreated patients. J Virol (1996) 2.50
Effect of 2',3'-didehydro-3'-deoxythymidine in an in vitro hollow-fiber pharmacodynamic model system correlates with results of dose-ranging clinical studies. Antimicrob Agents Chemother (1994) 2.46
Follicular helper T cells serve as the major CD4 T cell compartment for HIV-1 infection, replication, and production. J Exp Med (2012) 2.46
Requirement of human immunodeficiency virus type 1 nef for in vivo replication and pathogenicity. J Virol (1994) 2.45
Mamu-A*01 allele-mediated attenuation of disease progression in simian-human immunodeficiency virus infection. J Virol (2002) 2.44
Cellular reservoirs of HIV-1 and their role in viral persistence. Curr HIV Res (2008) 2.40
Simian immunodeficiency virus replicates to high levels in naturally infected African green monkeys without inducing immunologic or neurologic disease. J Virol (2001) 2.29
Activation of virus replication after vaccination of HIV-1-infected individuals. J Exp Med (1995) 2.26
Mutations in the tat gene are responsible for human immunodeficiency virus type 1 postintegration latency in the U1 cell line. J Virol (1998) 2.23
A partially attenuated simian immunodeficiency virus induces host immunity that correlates with resistance to pathogenic virus challenge. J Virol (1994) 2.23
Abnormal activation and cytokine spectra in lymph nodes of people chronically infected with HIV-1. Blood (2007) 2.21
Evolution of envelope sequences from the genital tract and peripheral blood of women infected with clade A human immunodeficiency virus type 1. J Virol (1998) 2.21
Cellular latency in human immunodeficiency virus-infected individuals with high CD4 levels can be detected by the presence of promoter-proximal transcripts. Proc Natl Acad Sci U S A (1994) 2.14
Reduction of HIV-1 in blood and lymph nodes following potent antiretroviral therapy and the virologic correlates of treatment failure. Proc Natl Acad Sci U S A (1997) 2.11
Absolute dependence on kappa B responsive elements for initiation and Tat-mediated amplification of HIV transcription in blood CD4 T lymphocytes. EMBO J (1995) 2.10
AIDS-related Burkitt lymphoma in the United States: what do age and CD4 lymphocyte patterns tell us about etiology and/or biology? Blood (2010) 2.10
In vivo distribution of the human immunodeficiency virus/simian immunodeficiency virus coreceptors: CXCR4, CCR3, and CCR5. J Virol (1998) 2.09
Upregulation of Fas ligand expression by human immunodeficiency virus in human macrophages mediates apoptosis of uninfected T lymphocytes. J Virol (1996) 2.07
A point mutation in the HIV-1 Tat responsive element is associated with postintegration latency. Proc Natl Acad Sci U S A (1996) 2.06
Natural SIV hosts: showing AIDS the door. Science (2012) 2.03
Residual immune dysregulation syndrome in treated HIV infection. Adv Immunol (2013) 2.01
Serum Vpr regulates productive infection and latency of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A (1994) 2.00
Accumulation of defective viral genomes in peripheral blood mononuclear cells of human immunodeficiency virus type 1-infected individuals. J Virol (1997) 2.00
Evidence for rapid disappearance of initially expanded HIV-specific CD8+ T cell clones during primary HIV infection. Proc Natl Acad Sci U S A (1997) 1.99
Human transcription factor YY1 represses human immunodeficiency virus type 1 transcription and virion production. J Virol (1994) 1.98
Constant mean viral copy number per infected cell in tissues regardless of high, low, or undetectable plasma HIV RNA. J Exp Med (1999) 1.96
Majority of CD4+ T cells from peripheral blood of HIV-1-infected individuals contain only one HIV DNA molecule. Proc Natl Acad Sci U S A (2011) 1.93
High viral load in lymph nodes and latent human immunodeficiency virus (HIV) in peripheral blood cells of HIV-1-infected chimpanzees. J Virol (1993) 1.93
HIV-1 Nef increases T cell activation in a stimulus-dependent manner. Proc Natl Acad Sci U S A (1999) 1.92
Human herpesvirus 6. Clin Microbiol Rev (1997) 1.91
Early events in tissues during infection with pathogenic (SIVmac239) and nonpathogenic (SIVmac1A11) molecular clones of simian immunodeficiency virus. Am J Pathol (1994) 1.91
Interleukin 1 induces expression of the human immunodeficiency virus alone and in synergy with interleukin 6 in chronically infected U1 cells: inhibition of inductive effects by the interleukin 1 receptor antagonist. Proc Natl Acad Sci U S A (1994) 1.84
B cells of HIV-1-infected patients bind virions through CD21-complement interactions and transmit infectious virus to activated T cells. J Exp Med (2000) 1.79
Long-acting three-drug combination anti-HIV nanoparticles enhance drug exposure in primate plasma and cells within lymph nodes and blood. AIDS (2014) 1.76
Extracellular Vpr protein increases cellular permissiveness to human immunodeficiency virus replication and reactivates virus from latency. J Virol (1995) 1.74
MT-2 cell tropism as prognostic marker for disease progression in human immunodeficiency virus type 1 infection. J Clin Microbiol (1994) 1.72
Primary stage of feline immunodeficiency virus infection: viral dissemination and cellular targets. J Virol (1994) 1.69
Cytotoxic T lymphocytes and viral turnover in HIV type 1 infection. Proc Natl Acad Sci U S A (1996) 1.68
Impaired response to HAART in HIV-infected individuals with high autonomic nervous system activity. Proc Natl Acad Sci U S A (2001) 1.68
Apoptosis induced in CD4+ cells expressing gp160 of human immunodeficiency virus type 1. J Virol (1994) 1.67
Highly restricted spread of HIV-1 and multiply infected cells within splenic germinal centers. Proc Natl Acad Sci U S A (2000) 1.65
Molecular determinants of acute single-cell lysis by human immunodeficiency virus type 1. J Virol (1996) 1.64
Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue. Antimicrob Agents Chemother (2005) 1.63
Regulation of human immunodeficiency virus type 1 and cytokine gene expression in myeloid cells by NF-kappa B/Rel transcription factors. Microbiol Rev (1995) 1.63
Characterization of a family of related cellular transcription factors which can modulate human immunodeficiency virus type 1 transcription in vitro. Mol Cell Biol (1994) 1.62
Variants from the diverse virus population identified at seroconversion of a clade A human immunodeficiency virus type 1-infected woman have distinct biological properties. J Virol (1999) 1.61
Activation of human immunodeficiency virus transcription in T cells revisited: NF-kappaB p65 stimulates transcriptional elongation. J Virol (2001) 1.61
Multiple organ infection and the pathogenesis of SARS. J Exp Med (2005) 1.58
CD4(+) T-cell depletion in HIV infection: mechanisms of immunological failure. Immunol Rev (2013) 1.58
Wide range of viral load in healthy african green monkeys naturally infected with simian immunodeficiency virus. J Virol (2000) 1.55
Kinetics of human immunodeficiency virus type 1 (HIV-1) DNA and RNA synthesis during primary HIV-1 infection. Proc Natl Acad Sci U S A (1993) 1.54
Use of human tissue explants to study human infectious agents. Nat Protoc (2009) 1.52
Analysis of the temporal relationship between human immunodeficiency virus type 1 quasispecies in sequential blood samples and various organs obtained at autopsy. J Virol (1998) 1.52
Tat protein induces human immunodeficiency virus type 1 (HIV-1) coreceptors and promotes infection with both macrophage-tropic and T-lymphotropic HIV-1 strains. J Virol (1998) 1.52
Expansion of pre-existing, lymph node-localized CD8+ T cells during supervised treatment interruptions in chronic HIV-1 infection. J Clin Invest (2002) 1.50
In vivo distribution and cytopathology of variants of human immunodeficiency virus type 1 showing restricted sequence variability in the V3 loop. J Virol (1994) 1.50
In vivo sequence variability of human immunodeficiency virus type 1 envelope gp120: association of V2 extension with slow disease progression. J Virol (1997) 1.48
Immunopathogenesis of oropharyngeal candidiasis in human immunodeficiency virus infection. Clin Microbiol Rev (2004) 1.48
Human immunodeficiency virus type 1 mRNA expression in peripheral blood cells predicts disease progression independently of the numbers of CD4+ lymphocytes. Proc Natl Acad Sci U S A (1994) 1.48
Heterozygosity for a defective gene for CC chemokine receptor 5 is not the sole determinant for the immunologic and virologic phenotype of HIV-infected long-term nonprogressors. J Clin Invest (1997) 1.46
Kinetics of cytokine expression during primary human immunodeficiency virus type 1 infection. Proc Natl Acad Sci U S A (1996) 1.44
Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci U S A (1997) 13.47
Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med (1992) 13.29
Detection of AIDS virus in macrophages in brain tissue from AIDS patients with encephalopathy. Science (1986) 11.74
Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome. N Engl J Med (1983) 10.09
Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T cell growth. J Exp Med (1986) 9.86
Efficient isolation and propagation of human immunodeficiency virus on recombinant colony-stimulating factor 1-treated monocytes. J Exp Med (1988) 9.21
The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum (1990) 8.92
The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritis Rheum (1990) 8.67
The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum (1990) 8.36
Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med (1983) 8.26
The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum (1990) 8.23
The reservoir for HIV-1 in human peripheral blood is a T cell that maintains expression of CD4. Science (1989) 7.90
Toward an understanding of the correlates of protective immunity to HIV infection. Science (1996) 7.59
Cytokine-induced expression of HIV-1 in a chronically infected promonocyte cell line. Science (1987) 7.22
The spectrum of vasculitis: clinical, pathologic, immunologic and therapeutic considerations. Ann Intern Med (1978) 7.17
p6Gag is required for particle production from full-length human immunodeficiency virus type 1 molecular clones expressing protease. J Virol (1995) 6.87
Biological and biochemical characterization of a cloned Leu-3- cell surviving infection with the acquired immune deficiency syndrome retrovirus. J Exp Med (1986) 6.52
Qualitative analysis of immune function in patients with the acquired immunodeficiency syndrome. Evidence for a selective defect in soluble antigen recognition. N Engl J Med (1985) 6.46
NIH conference. Acquired immunodeficiency syndrome: epidemiologic, clinical, immunologic, and therapeutic considerations. Ann Intern Med (1984) 6.45
Tumor necrosis factor alpha activates human immunodeficiency virus type 1 through induction of nuclear factor binding to the NF-kappa B sites in the long terminal repeat. Proc Natl Acad Sci U S A (1989) 6.32
Tumor necrosis factor alpha induces expression of human immunodeficiency virus in a chronically infected T-cell clone. Proc Natl Acad Sci U S A (1989) 6.32
The human immunodeficiency virus type 1-specific protein vpu is required for efficient virus maturation and release. J Virol (1990) 6.08
Monokine regulation of human immunodeficiency virus-1 expression in a chronically infected human T cell clone. J Immunol (1989) 6.02
Takayasu arteritis. Ann Intern Med (1994) 5.94
Formaldehyde fixation. J Histochem Cytochem (1985) 5.89
The T/ebp null mouse: thyroid-specific enhancer-binding protein is essential for the organogenesis of the thyroid, lung, ventral forebrain, and pituitary. Genes Dev (1996) 5.71
Studies in subjects with long-term nonprogressive human immunodeficiency virus infection. N Engl J Med (1995) 5.69
Major expansion of CD8+ T cells with a predominant V beta usage during the primary immune response to HIV. Nature (1994) 5.68
Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. Proc Natl Acad Sci U S A (1998) 5.48
New concepts in the immunopathogenesis of human immunodeficiency virus infection. N Engl J Med (1993) 5.32
HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc Natl Acad Sci U S A (1999) 5.25
Transforming growth factor beta is an important immunomodulatory protein for human B lymphocytes. J Immunol (1986) 5.19
Glucocorticosteroid therapy: mechanisms of action and clinical considerations. Ann Intern Med (1976) 5.16
Structural characterization of reverse transcriptase and endonuclease polypeptides of the acquired immunodeficiency syndrome retrovirus. J Virol (1986) 5.05
The effect of in vivo hydrocortisone on subpopulations of human lymphocytes. J Clin Invest (1974) 4.90
Wegener's granulomatosis: studies in eighteen patients and a review of the literature. Medicine (Baltimore) (1973) 4.89
Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy. Nat Med (2000) 4.83
Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy. Nat Med (1999) 4.81
Human immunodeficiency virus infection among patients attending clinics for sexually transmitted diseases. N Engl J Med (1988) 4.81
Preferential infection of CD4+ memory T cells by human immunodeficiency virus type 1: evidence for a role in the selective T-cell functional defects observed in infected individuals. Proc Natl Acad Sci U S A (1990) 4.80
Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1. N Engl J Med (1996) 4.72
NIH conference. The idiopathic hypereosinophilic syndrome. Clinical, pathophysiologic, and therapeutic considerations. Ann Intern Med (1982) 4.70
Transfer of HIV-1-specific cytotoxic T lymphocytes to an AIDS patient leads to selection for mutant HIV variants and subsequent disease progression. Nat Med (1995) 4.65
Relative resistance to HIV-1 infection of CD4 lymphocytes from persons who remain uninfected despite multiple high-risk sexual exposure. Nat Med (1996) 4.57
The American College of Rheumatology 1990 criteria for the classification of Henoch-Schönlein purpura. Arthritis Rheum (1990) 4.43
Single amino acid changes in the human immunodeficiency virus type 1 matrix protein block virus particle production. J Virol (1994) 4.40
Multiple effects of mutations in human immunodeficiency virus type 1 integrase on viral replication. J Virol (1995) 4.27
Lymphoid organs function as major reservoirs for human immunodeficiency virus. Proc Natl Acad Sci U S A (1991) 4.23
HIV. An elusive soluble suppressor. Nature (1995) 4.18
The macrophage in the persistence and pathogenesis of HIV infection. AIDS (1989) 4.06
PA-457: a potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing. Proc Natl Acad Sci U S A (2003) 4.03
Sjögren's syndrome (Sicca syndrome): current issues. Ann Intern Med (1980) 3.81
Induction of HTLV-III/LAV from a nonvirus-producing T-cell line: implications for latency. Science (1986) 3.80
Viral dynamics of primary viremia and antiretroviral therapy in simian immunodeficiency virus infection. J Virol (1997) 3.79
The extent of early viral replication is a critical determinant of the natural history of simian immunodeficiency virus infection. J Virol (1997) 3.77
Influence of surface characteristics on bone integration of titanium implants. A histomorphometric study in miniature pigs. J Biomed Mater Res (1991) 3.57
Re-emergence of HIV after stopping therapy. Nature (1999) 3.54
AIDS--an immunologic reevaluation. N Engl J Med (1984) 3.53
Circulating CD8+ cytotoxic T lymphocytes specific for HTLV-I pX in patients with HTLV-I associated neurological disease. Nature (1990) 3.50
Characterization of a promonocyte clone chronically infected with HIV and inducible by 13-phorbol-12-myristate acetate. J Immunol (1988) 3.45
Interferon-alpha but not AZT suppresses HIV expression in chronically infected cell lines. Science (1989) 3.43
Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection. J Infect Dis (1997) 3.35
A mutant of human immunodeficiency virus with reduced RNA packaging and abnormal particle morphology. J Virol (1990) 3.33
Detailed studies on expression and function of CD19 surface determinant by using B43 monoclonal antibody and the clinical potential of anti-CD19 immunotoxins. Blood (1988) 3.30
Effects of transforming growth factor beta on the functions of natural killer cells: depressed cytolytic activity and blunting of interferon responsiveness. J Immunol (1986) 3.29
Megestrol acetate in patients with AIDS-related cachexia. Ann Intern Med (1994) 3.25
Enteropathy associated with the acquired immunodeficiency syndrome. Ann Intern Med (1984) 3.22
Transmission of HTLV-III infection from human plasma to chimpanzees: an animal model for AIDS. Science (1984) 3.20
Immunologic abnormalities in the acquired immunodeficiency syndrome. Annu Rev Immunol (1985) 3.19
Tumor necrosis factor alpha functions in an autocrine manner in the induction of human immunodeficiency virus expression. Proc Natl Acad Sci U S A (1990) 3.18
Lymphoid germinal centers are reservoirs of human immunodeficiency virus type 1 RNA. J Infect Dis (1991) 3.16
Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses (2000) 3.13
Susceptibility of normal human lymphocytes to infection with HTLV-III/LAV. J Immunol (1986) 3.12
Induction of HIV-1 replication in latently infected CD4+ T cells using a combination of cytokines. J Exp Med (1998) 3.11
Immunoregulatory aberrations in systemic lupus erythematosus. J Immunol (1978) 3.07
Bacteremia due to Mycobacterium avium-intracellulare in the acquired immunodeficiency syndrome. Ann Intern Med (1983) 3.06
Characterization of a monoclonal antibody (4F2) that binds to human monocytes and to a subset of activated lymphocytes. J Immunol (1981) 3.02
Latent reservoirs of HIV: obstacles to the eradication of virus. Proc Natl Acad Sci U S A (1999) 3.00
Isolation and characterization of a new human microsporidian, Encephalitozoon hellem (n. sp.), from three AIDS patients with keratoconjunctivitis. J Infect Dis (1991) 2.95
Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro. J Clin Invest (1995) 2.95
Macrophage-tropic HIV and SIV envelope proteins induce a signal through the CCR5 chemokine receptor. Nature (1997) 2.94
Association between active Wegener's granulomatosis and anticytoplasmic antibodies. Arch Intern Med (1989) 2.94
Lack of evidence for the dichotomy of TH1 and TH2 predominance in HIV-infected individuals. Science (1994) 2.92
The cardiovascular manifestations of the hypereosinophilic syndrome. Prospective study of 26 patients, with review of the literature. Am J Med (1979) 2.86